Skip to main content
Explore URMC

menu

Acute Myeloid Leukemia (AML): Crenolanib Versus Midostaurin in Newly Diagnosed Subjects With FLT3 Mutated AML

Research Question:
Does the drug Crenolanib help patients with acute myeloid leukemia survive?

Basic Study Information

Purpose:
This purpose of this study is to compare the efficacy of crenolanib with midostaurin administered following induction chemotherapy and consolidation therapy on event-free survival in newly diagnosed acute myeloid leukemia subjects with FLT3 mutation.

Study Reference #: ILEU17106

Lead Researcher (Principal Investigator)

Lead Researcher: Jane Liesveld, MD

Study Contact Information

Study Coordinator: Haley Misch
Phone: (585) 275-9485

Additional Study Details

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search